{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:20:20Z","timestamp":1794774020507,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes &amp; Endocrinology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/s2213-8587(20)30240-0","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T18:41:49Z","timestamp":1595875309000},"page":"748-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase"],"prefix":"10.1016","volume":"8","author":[{"given":"Rosario","family":"Pivonello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Newell-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattana","family":"Leelawattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jig","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Laplanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libuse","family":"Tauchmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M K","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2213-8587(20)30240-0_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(20)30240-0_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/S2213-8587(20)30240-0_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(20)30240-0_bib6","doi-asserted-by":"crossref","first-page":"R227","DOI":"10.1530\/EJE-14-0883","article-title":"Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence","volume":"172","author":"Petersenn","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4158\/EP161512.DSCR","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: diagnosis of recurrence in Cushing disease","volume":"22","author":"Fleseriu","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/S2213-8587(20)30240-0_bib8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(20)30240-0_bib12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib14","series-title":"Beck Depression Inventory","author":"Beck","year":"1996"},{"key":"10.1016\/S2213-8587(20)30240-0_bib16","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1017\/S0033291715001270","article-title":"Minimal clinically important difference on the Beck Depression Inventory\u2014II according to the patient's perspective","volume":"45","author":"Button","year":"2015","journal-title":"Psychol Med"},{"key":"10.1016\/S2213-8587(20)30240-0_bib17","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.13600","article-title":"Worse health-related quality of life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN","volume":"88","author":"Valassi","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/S2213-8587(20)30240-0_bib20","first-page":"3083","article-title":"Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels","volume":"83","author":"Lado-Abeal","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib21","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib23","doi-asserted-by":"crossref","first-page":"e1933","DOI":"10.1073\/pnas.1621082114","article-title":"Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11\u03b2-hydroxylase deficiency","volume":"114","author":"Khattab","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S2213-8587(20)30240-0_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2009-0651","article-title":"Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency","volume":"95","author":"Parajes","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1530\/EJE-13-0737","article-title":"Characterisation of three novel CYP11B1 mutations in classic and non-classic 11\u03b2-hydroxylase deficiency","volume":"170","author":"Polat","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib26","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1210\/jc.2013-1306","article-title":"A diagnosis not to be missed: nonclassic steroid 11\u03b2-hydroxylase deficiency presenting with premature adrenarche and hirsutism","volume":"98","author":"Reisch","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(20)30240-0_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13048-018-0450-8","article-title":"Non-classical 11\u03b2-hydroxylase deficiency caused by compound heterozygous mutations: a case study and literature review","volume":"11","author":"Wang","year":"2018","journal-title":"J Ovarian Res"},{"issue":"suppl 10","key":"10.1016\/S2213-8587(20)30240-0_bib28","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects","volume":"55","author":"Menard","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S2213-8587(20)30240-0_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/S2213-8587(20)30240-0_bib30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11102-012-0452-2","article-title":"Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease","volume":"16","author":"van der Pas","year":"2013","journal-title":"Pituitary"}],"updated-by":[{"DOI":"10.1016\/s2213-8587(20)30275-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["The Lancet Diabetes &amp; Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858720302400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858720302400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:08:09Z","timestamp":1761991689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858720302400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2213858720302400"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(20)30240-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738411823.793584798","asserted-by":"object"}]},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}